CodeMap® Compliance Briefing: June 3, 2021

Editor's Welcome:

Even as the pandemic resides, we continue to receive inquiries about laboratory practices that have developed as a result of the strange and disruptive period caused by COVID-19. Recently, we have received multiple email inquiries concerning Medicare's direct billing rules. Many of these inquiries are from laboratories, which were forced to send out increased volumes of testing to outside, reference labs due to labor shortages, stay-at-home orders, and/or supply chain disruptions. Considering these inquiries, we decided that now is a good time to revisit Medicare's direct billing rules, in particular, the 70/30 rule. We also chose to discuss how the 70/30 rule applies to tests and procedures described by MAAA and....

Sorry, access to this content requires a current subscription.

Click here for publications catalog.

CPT copyright 2024 American Medical Association. All rights reserved.

* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, nonuse, or interpretation of information contained in this product.